<DOC>
	<DOCNO>NCT00351091</DOCNO>
	<brief_summary>The primary objective pilot study estimate percent change baseline Week 4 , Month 6 NTX bone turnover marker monthly 150mg dose risedronate administer 6 month load dose regimen risedronate 6 month treatment period compare 5 mg daily dose risedronate 6 month The secondary objective : - To estimate percent change baseline specify visit Week 4 , Month 6 NTX monthly 150 mg dose risedronate administer 6 month load dose regimen risedronate 6 month treatment period compare 5 mg daily dose risedronate . - To estimate percent change baseline specify visit serum CTX bone specific alkaline phosphatase monthly 150 mg dose risedronate administer 6 month load dose regimen risedronate 6 month treatment period compare 5 mg daily risedronate . - To estimate percent change baseline Month 6 lumbar spine BMD monthly 150 mg dose risedronate administer 6 month load dose regimen risedronate 6 month treatment period compare 5 mg daily dose risedronate . - To evaluate safety risedronate 150 mg monthly load dose regimen .</brief_summary>
	<brief_title>Risedronate Postmenopausal Women With Low Bone Density</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>ambulatory woman , postmenopausal &gt; = 5 year lumbar spine baseline BMD within follow criterion : Hologic : &lt; = 0.827 g/cm2 Lunar : &lt; = 0.942 g/cm2 Norland : &lt; = 0.768 g/cm2 general good health determine medical history , physical examination laboratory test serum 25OH vitamin D level &lt; = 12 ng/ml history osteomalacia history active hyperparathyroidism hyperthyroidism hypocalcemia hypercalcemia cause depot injection &gt; 10,000 IU Vitamin D past 9 month prior start investigational product use Vitamin D supplementation within 3 month prior start investigational product use follow medication within specified number month prior start investigational product : bisphosphonate . use fluoride exception fluoride use oral hygiene strontium bone active agent subcutaneous estrogen implant oral parenteral glucocorticoid anabolic steroid estrogen estrogenrelated drug , except low dose vaginal cream progestogen calcitonin , calcitriol , calcifediol allergic abnormal reaction bisphosphonates creatinine clearance &lt; 30 ml/min</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>